Edoxaban for the Long-Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?

Giuseppe Camporese, Paolo Simioni, Pierpaolo Di Micco, Carmen Fernández-Capitán, Agustina Rivas, Carme Font, Joan Carles Sahuquillo, Paula Villares, Paolo Prandoni, Manuel Monreal, RIETE Investigators, Giuseppe Camporese, Paolo Simioni, Pierpaolo Di Micco, Carmen Fernández-Capitán, Agustina Rivas, Carme Font, Joan Carles Sahuquillo, Paula Villares, Paolo Prandoni, Manuel Monreal, RIETE Investigators

Abstract

Edoxaban is used for venous thromboembolism (VTE) treatment. Real-life data are lacking about its use in long-term therapy. We aimed to assess the efficacy and the safety of edoxaban for long-term VTE treatment in a real-life setting. Patients with VTE included in the Registro Informatizado Enfermedad TromboEmbólica (RIETE) registry, receiving edoxaban 60 or 30 mg daily were prospectively followed up to validate the benefit of using different dosages. The main outcome was the composite of VTE recurrences or major bleeding in patients with or without criteria for dose reduction. Multivariable analysis to identify predictors for the composite outcome was performed. From October 2015 to November 2019, 562 patients received edoxaban for long-term therapy. Most (94%) of the 416 patients not meeting criteria for dose reduction received 60 mg daily, and 92 patients meeting criteria (63%) received 30 mg daily. During treatment, two patients developed recurrent VTE, six had major bleeding and nine died (2 from fatal bleeding). Among patients not meeting criteria for dose reduction, those receiving 30 mg daily had a higher rate of the composite event (hazard ratio (HR) 8.37; 95% confidence interval (CI) 1.12-42.4) and a significant higher mortality rate (HR 31.1; 95% CI 4.63-262) than those receiving 60 mg. Among patients meeting criteria for dose reduction, those receiving 60 mg daily had no events, and a nonsignificantly higher mortality rate (HR 5.04; 95% CI 0.54-133) than those receiving 30 mg daily. In conclusion, edoxaban seems to be effective and safe for long-term VTE treatment in real life. Criteria for dose reduction should be reformulated.

Trial registration: ClinicalTrials.gov NCT02832245.

Conflict of interest statement

The authors declared no competing interests for this work.

© 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society of Clinical Pharmacology & Therapeutics.

Figures

Figure 1
Figure 1
Proportion of patients receiving low‐molecular‐weight heparin (LMWH), vitamin K antagonists (VKAs), or direct oral anticoagulants for long‐term therapy over time.

References

    1. Kearon, C. et al Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149, 315–352 (2016).
    1. Konstantinides, S.V. et al ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur. Heart J. 2019, 1–61 (2019).
    1. Bauersachs, R. et al Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363, 2499–2510 (2010).
    1. Agnelli, G. et al Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 369, 799–808 (2013).
    1. Buller, H.R. et al Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. 369, 1406–1415 (2013).
    1. Buller, H.R. et al Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366, 1287–1297 (2012).
    1. Schulman, S. et al Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342–2352 (2009).
    1. Romualdi, E. , Donadini, M.P. & Ageno, W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN‐extension study). Expert Rev. Cardiovasc. Ther. 9, 841–844 (2011).
    1. Liu, X. et al Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY‐EXT trial. Thromb. Haemost. 115, 161–168 (2016).
    1. Schulman, S. et al Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med. 368, 709–718 (2013).
    1. Weitz, J.I. et al Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N. Engl. J. Med. 376, 1211–1222 (2017).
    1. Cohen, A.T. et al Design and rationale of the non‐interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA‐VTE‐Europe) study. Thromb. J. 16, 9 (2018).
    1. De Caterina, R. et al The global edoxaban treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design. Clin. Cardiol. 42, 1147–1154 (2019).
    1. Jiménez, D. et al Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. BMJ 366, l4416 (2019).
    1. Bikdeli, B. et al Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb. Haemost. 118, 214–224 (2018).
    1. Ruff, C.T. et al Association between edoxaban dose, concentration, anti‐Factor X activity, and outcomes: an analysis of data from the randomised, double blind ENGAGE AF‐TIMI 48 trial. Lancet 385, 2288–2295 (2015).
    1. Koretsune, Y. , Yamashita, T. , Kimura, T. , Fukuzawa, M. , Abe, K. & Yasaka, M. Short‐term safety and plasma concentrations of edoxaban in Japanese patients with non‐valvular atrial fibrillation and severe renal impairment. Circ. J. 79, 1486–1495 (2015).
    1. Fazio, G. , Dentamaro, I. , Gambacurta, R. , Alcamo, P. & Colonna, P. Safety of edoxaban 30 mg in elderly patients with severe renal impairment. Clin. Drug Invest. 38, 1023–1030 (2018).

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa